Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière’s Disease

Table 1

Results of the Consensus Conference on the use and dosage of betahistine during the intercritical phase of MD. 1 = absolutely disagree, 2 = disagree, 3 = agree, 4 = more than agree, and 5 = absolutely agree. Consensus was reached when the sum of items 1 and 2 or 3, 4, and 5 reached 66%. Asterisk explanations: Negative consensus, No consensus, and Positive consensus.

	1	2	3	4	5
In the inter-critical phase therapy, referred to the vertigo in the Menière’s disease, do you think that betahistine:
1. Is useful	8%	5%	41%	23%	23%
	13		87
2. Is useful only when associated to other therapies	8%	66%	12%	12%	2%
	74		26
3. It’s the first-choice drug	3%	26%	19%	26%	26%
	29		71
4. Shows poor efficacy	49%	45%	2%	4%	0%
	94		6
If you use Betahistine for prophylaxis what is the dosage that you use:
1. I do not use	45%	36%	6%	3%	10%
	81		19
2. I use in the range from 8 to 32 mg/day	21%	64%	9%	3%	3%
	85		15
3. I use in the range from 32 to 48 mg/day	3%	0%	41%	29%	17%
	3		97
4. I use higher than 48 mg/day	4%	31%	50%	6%	9%
	35		65
5. Vary in the course of time	3%	19%	54%	8%	16%
	22		78